Navigating TAM receptor dynamics in tumour immunotherapy

被引:0
作者
Yang, Jihao [1 ]
Chen, Guanmin [1 ]
Wang, Rui [1 ]
Song, Chengcheng [1 ]
Yi, Huaqiang [1 ]
机构
[1] Shandong Univ Tradit Chinese, Sch Acupuncture & Tuina, Med, Jinan 250013, Peoples R China
关键词
TAM receptor; TYRO3; AXL; MERTK; Tumour; TO-MESENCHYMAL TRANSITION; AXL MEDIATES RESISTANCE; TYROSINE KINASE TYRO3; CANCER METASTASIS; DRUG-RESISTANCE; DENDRITIC CELLS; TARGETING AXL; PROTEIN-S; ACTIVATION; LEUKEMIA;
D O I
10.1007/s00262-024-03879-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The TAM receptor family is getting more and more attention in the field of tumour immunity. Activation of TAM receptors not only aids in the survival and multiplication of tumour cells but also increases their likelihood of invading other cells and spreading. In addition, activation of TAM receptors helps to inhibit the anti-tumour immune response, allowing tumour cells to evade immune surveillance. In terms of therapeutic strategies, a number of inhibitors targeting TAM receptors are in preclinical and clinical development. Despite significant progress in clinical trials in recent years, challenges remain. This review delves into the kinetic characteristics of the TAM receptor family, their dual role in tumour immunity, and the transmission process of downstream signalling pathways. Based on this, we analysed and summarised the unique strategies and combination therapies for regulating tumour immunity using TAM receptor inhibitors. It not only helps to elucidate the key role of TAM receptors in tumour immunity but also provides new perspectives and strategies for future tumour therapy.
引用
收藏
页数:14
相关论文
共 116 条
  • [1] Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
    Abou-Alfa, G. K.
    Meyer, T.
    Cheng, A. -L.
    El-Khoueiry, A. B.
    Rimassa, L.
    Ryoo, B. -Y.
    Cicin, I.
    Merle, P.
    Chen, Y. H.
    Park, J. -W.
    Blanc, J. -F.
    Bolondi, L.
    Klumpen, H. -J.
    Chan, S. L.
    Zagonel, V.
    Pressiani, T.
    Ryu, M. -H.
    Venook, A. P.
    Hessel, C.
    Borgman-Hagey, A. E.
    Schwab, G.
    Kelley, R. K.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (01) : 54 - 63
  • [2] Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
    Adam-Artigues, Anna
    Arenas, Enrique J.
    Martinez-Sabadell, Alex
    Braso-Maristany, Fara
    Cervera, Raimundo
    Tormo, Eduardo
    Hernando, Cristina
    Teresa Martinez, Maria
    Carbonell-Asins, Juan
    Simon, Soraya
    Poveda, Jesus
    Moragon, Santiago
    Zazo, Sandra
    Martinez, Debora
    Rovira, Ana
    Burgues, Octavio
    Rojo, Federico
    Albanell, Joan
    Bermejo, Begona
    Lluch, Ana
    Prat, Aleix
    Arribas, Joaquin
    Eroles, Pilar
    Miguel Cejalvo, Juan
    [J]. SCIENCE ADVANCES, 2022, 8 (20):
  • [3] TAM Receptor Inhibition-Implications for Cancer and the Immune System
    Aehnlich, Pia
    Powell, Richard Morgan
    Peeters, Marlies J. W.
    Rahbech, Anne
    Thor Straten, Per
    [J]. CANCERS, 2021, 13 (06) : 1 - 16
  • [4] Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase
    Aguilera, Todd A.
    Giaccia, Amato J.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (12) : 2928 - 2933
  • [5] Reprogramming the immunological microenvironment through radiation and targeting Axl
    Aguilera, Todd A.
    Rafat, Marjan
    Castellini, Laura
    Shehade, Hussein
    Kariolis, Mihalis S.
    Hui, Angela Bik-Yu
    Stehr, Henning
    von Eyben, Rie
    Jiang, Dadi
    Ellies, Lesley G.
    Koong, Albert C.
    Diehn, Maximilian
    Rankin, Erinn B.
    Graves, Edward E.
    Giaccia, Amato J.
    [J]. NATURE COMMUNICATIONS, 2016, 7
  • [6] Axl/Gas6/NFκB signalling in schwannoma pathological proliferation, adhesion and survival
    Ammoun, S.
    Provenzano, L.
    Zhou, L.
    Barczyk, M.
    Evans, K.
    Hilton, D. A.
    Hafizi, S.
    Hanemann, C. O.
    [J]. ONCOGENE, 2014, 33 (03) : 336 - 346
  • [7] The GAS6-AXL signaling network is a mesenchymal (Mes) molecular subtype-specific therapeutic target for ovarian cancer
    Antony, Jane
    Tan, Tuan Zea
    Kelly, Zoe
    Low, Jeffrey
    Choolani, Mahesh
    Recchi, Chiara
    Gabra, Hani
    Thiery, Jean Paul
    Huang, Ruby Yun-Ju
    [J]. SCIENCE SIGNALING, 2016, 9 (448)
  • [8] AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells
    Asiedu, M. K.
    Beauchamp-Perez, F. D.
    Ingle, J. N.
    Behrens, M. D.
    Radisky, D. C.
    Knutson, K. L.
    [J]. ONCOGENE, 2014, 33 (10) : 1316 - 1324
  • [9] AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew
    Auyez, Almira
    Sayan, A. Emre
    Kriajevska, Marina
    Tulchinsky, Eugene
    [J]. CANCERS, 2021, 13 (19)
  • [10] Axl as a mediator of cellular growth and survival
    Axelrod, Haley
    Pienta, Kenneth J.
    [J]. ONCOTARGET, 2014, 5 (19) : 1 - 35